Gland Pharma Shares Surge 16% to New 52-Week High Amid Market Turbulence.

Gland Pharma Surges to 52-Week High After Reporting Strong Q4 Results

Gland Pharma shares jumped over 16% in early trade on Monday, reaching a fresh 52-week high of ₹2,170 apiece on the BSE, despite the broader Indian stock market crash. The benchmark Sensex cracked over 900 points, while the Nifty 50 declined over 1% to slip below the 23,400 level.

The rally in Gland Pharma shares comes after the company reported better-than-expected Q4 results. The company's consolidated net profit spiked 96.6% year-on-year (YoY) for the fourth quarter of FY26 to ₹366.6 crore, supported by higher revenue and improved operating performance.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Revenue in Q4FY26 grew 22.3% to ₹1,742.7 crore from ₹1,424.9 crore, YoY. The CDMO business contributed 46% of revenues, growing 36% YoY in Q4FY26 and 28% for FY26.

At the operational front, EBITDA increased 47.6% to ₹512.9 crore from ₹347.4 crore, while EBITDA margin expanded to 29.4% from 24.4%, YoY.

Brokerage firm Motilal Oswal Financial Services raised its earnings estimates by 8% and 10% for FY27 and FY28, factoring in a healthy pace of product launches in core markets, an improvement in profitability of the Cenexi business, and currency depreciation tailwinds. It expects a 19% earnings CAGR over FY26-28 on the back of a complex product pipeline comprising injectables, the scale-up of CDMO contracts, and improved synergy from Cenexi.

Motilal Oswal reiterates its 'Buy' rating on Gland Pharma shares and values the stock at 27x 12-month forward earnings to arrive at a target price of ₹2,300 apiece.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Gland Pharma share price has rallied 17% in one month and has gained 22% on a year-to-date (YTD) basis. The pharma stock has jumped 43% in one year and has surged 57% over the past three years. At 9:50 AM, Gland Pharma share price was trading 13.05% higher at ₹2,110.70 apiece on the BSE.